EUCTR2009-009214-40-BE进行中（未招募）1 期
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECTED SUBJECTS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1. Male or female subjects at least 18 years of age.
- •2.A negative pregnancy test at Screening and immediately prior to start of study medication for Women of Child Bearing Potential (WOCBP).
- •NOTE: WOCBP includes any female who has experienced menarche and who has not undergone hysterectomy, bilateral oophorectomy or tubal ligation or is not post-menopausal (aged >45, amennorheic for >2 years, and serum FSH levels >30 IU/L). Even women who are using mechanical products (intrauterine devices; barrier methods) to prevent pregnancy, who are practicing abstinence, or who have a partner that is sterile (eg, vasectomy), should be considered to be of child bearing potential.
- •3. Willingness to utilize effective barrier contraception for WOCBP, males and their
- •partners, throughout the duration of the study and for at least 7 months following the last dose of study medication. In addition, WOCBP must use another acceptable
- •method of contraception from screening to at least 6 months after the trial.
- •Acceptable contraception includes highly effective intrauterine devices or
- •vasectomised partner. NOTE: oral, transdermal, implantable, or injectable hormone
- •therapy is NOT allowed.
- •4. HCV seropositive.
- •5. HCV RNA =10,000 IU/mL at screening.
- •6. HCV Genotype 1. Subjects infected with a non-genotype 1 strain or mixed genotypes are not eligible.
- •7. Treatment naïve (no prior treatment with IFN-alpha+/- RBV regimens or investigational anti-HCV agents).
- •8. Liver biopsy within two years (24 months) of Screening with non-cirrhotic fibrosis classification (Ishak score =4 or equivalent). A copy of the pathology report must be available at the study site prior to randomization. For those subjects with liver biopsy outside of the time window or for those subjects with no history of liver biopsy, a biopsy must be performed prior to randomization.
- •9. Ultrasound within 6 months of Screening for 1) those subjects with bridging fibrosis or 2) those subjects with alpha-fetoprotein (AFP) >50 and <100 ng/mL with no evidence of hepatocellular carcinoma. For those subjects with an ultrasound conducted outside the 6-month time window, an ultrasound must be performed prior to randomization.
- •10. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •11. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will not be included in the trial:
- •1. Co-infection with either HIV or HBV.
- •2. Infection with a non-genotype 1 strain of HCV or mixed genotypes.
- •3. Evidence of severe or decompensated liver disease, as evidenced but not
- •limited to by any of the following at Screening:
- •a. Child-Pugh score >6;
- •b. Total serum bilirubin >2.5X ULN and direct bilirubin >1.5X ULN;
- •c. Serum albumin <2.0 g/dL;
- •d. Prothrombin time >1.5X ULN or INR >2.0X ULN;
- •e. AST or ALT >10X ULN;
- •f. History of ascites, bleeding varices, hepatic encephalopathy or hepatocellular carcinoma.
- •4. Subjects with liver disease unrelated to HCV infection including but not limited to:
- •a. Hemochromatosis;
- •b. Genetic liver disease:
- •1. Alpha-1 antitrypsin deficiency;
- •2. Wilson’s disease.
- •c. Auto-immune disease;
- •1. Auto-immune hepatitis;
- •2. Auto-immune cholestatic disease.
- •d. Drug induced liver disease (history of ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months;
- •e. Cholestatic liver disease; bile duct obstruction;
- •f. Alpha-fetoprotein (AFP) levels greater than 100 ng/ml;
- •g. Malignant neoplastic disease;
- •5. Pre-existing medical condition that makes the subject unsuitable for treatment with pegIFN alpha/RBV therapy per product labeling including, but not limited to:
- •a. Ocular abnormalities such as retinopathy, cotton wool spots, optic nerve
- •disorders, retinal hemorrhage; etc.
- •b. Major psychiatric disorders (severe depression, schizophrenia, psychosis, or a history of a suicide attempt).
- •6. Laboratory abnormality at Screening that makes the subject unsuitable for treatment
- •with pegIFN alpha/RBV therapy per product labeling including, but not limited to:
- •a. HbA1c >8.5%;
- •b. Estimated creatinine clearance of <50 mL/min;
- •c. Thyroid-stimulating hormone >1.2 x ULN or <0.8 x LLN (euthyroid subjects
- •exempt if euthyroid function is confirmed by T4/T3 testing);
- •d. ANA >1:640;
- •e. Hematologic abnormalities: hemoglobin <12 g/dL (women) or <13 g/dL (men),
- •platelet count <120,000 cells/mm3, and/or neutrophil count <1,500 cells/mm3;
- •7. Abnormal ECG suggestive of clinically significant cardiac disease or QTc >450 msec at screening.
- •8. History of solid organ transplant.
- •9. Contraindicated medications being taken by the subject at the time of randomization that must be continued during the study period, including potent CYP3A4 inhibitors, sensitive CYP3A4 substrates, CYP3A4 substrates with narrow therapeutic range and CYP3A4 inducers.
- •10. Have the following reproductive hormones outside the specified normal limits (males only):
- •Total Reference Range(Conventional) Reference Range (SI)
- •Testosterone 1.75-7.81 ng/mL 6.07-27.10 nmol/L
- •LH 2.0-12.0 mIU/mL 2.0-12.0 IU/L
- •FSH 1.13-12.51 mIU/mL 1.13-12.51 IU/L
- •11. Active alcohol or substance abuse sufficient, in the Investigator’s judgment, to prevent adherence to study medication and/or follow-up;
- •12. Pregnant or nursing females;
- •13. Males whose female partner is pregnant;
- •14. Unwilling or unable to comply with the Lifestyle guidelines (eg, no active drug or alcohol abuse);
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate whether a potential new drug is an effective and safe way to make damaged kidneys work better in patients with type II diabetesEUCTR2010-021358-20-GBPfizer Inc. 235 east 42nd Street, New York, NY 10017256
进行中（未招募）
不适用
A research study to determine if VP 20621 can prevent another episode of Clostridium difficile infection (CDI) in adults who were already treated for CDIClostridium difficile infectionMedDRA version: 14.1Level: LLTClassification code 10054236Term: Clostridium difficile infectionSystem Organ Class: 100000004862EUCTR2010-020484-20-DEViroPharma Incorporated174
进行中（未招募）
1 期
A clinical study to evaluate the effects and safety of three doses of Tofacitinib (a drug that is being investigated for the treatment of rheumatoid arthritis) in subjects with active Ankylosing spondylitis (AS) (a form of Arthritis)Ankylosing Spondylitis (AS)MedDRA version: 17.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-005689-39-SKPfizer Inc. 235 East 42nd Street, New York, 10017208
未知
不适用
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETESAND OVERT NEPHROPATHY-E112 Non-insulin-dependent diabetes mellitus, with renal complicationsNon-insulin-dependent diabetes mellitus, with renal complicationsE112PER-039-13PFIZER S.A.,10
进行中（未招募）
1 期
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSISEUCTR2018-004431-79-GBCelgene Corporation300